Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Thijssen

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Blood|February 10, 2022
Overcoming resistance hurdlesRachel Thijssen
Blood|June 25, 2026
Single-cell tracking of the fittest in AMLRachel Thijssen
Cancer Cell|October 16, 2019
Venetoclax in Lymphoid Malignancies: New Insights, More to LearnRachel Thijssen, Andrew W Roberts
Cancers|November 17, 2020
BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the ClinicVictor S Lin, Zhuo-Fan Xu, David C S Huang, et al.
Nucleic Acids Research|June 27, 2022
RUV-III-NB: normalization of single cell RNA-seq dataAgus Salim, Ramyar Molania, Jianan Wang, et al.
Cell Death and Differentiation|January 26, 2021
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLLMarco Haselager, Rachel Thijssen, Christopher West, et al.
Haematologica|May 10, 2015
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitorsRachel Thijssen, Erik Slinger, Katinka Weller, et al.
Cell Death and Differentiation|June 20, 2020
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cellsRachel Thijssen, Silvia Alvarez-Diaz, Clea Grace, et al.
Molecular Oncology|December 23, 2022
JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XLMarco V Haselager, Rachel Thijssen, Danique Bax, et al.
Oncogene|November 28, 2019
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphomaMichael A Dengler, Charis E Teh, Rachel Thijssen, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Blood|February 10, 2022
Overcoming resistance hurdlesRachel Thijssen
Blood|June 25, 2026
Single-cell tracking of the fittest in AMLRachel Thijssen
Cancer Cell|October 16, 2019
Venetoclax in Lymphoid Malignancies: New Insights, More to LearnRachel Thijssen, Andrew W Roberts
Cancers|November 17, 2020
BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the ClinicVictor S Lin, Zhuo-Fan Xu, David C S Huang, et al.
Nucleic Acids Research|June 27, 2022
RUV-III-NB: normalization of single cell RNA-seq dataAgus Salim, Ramyar Molania, Jianan Wang, et al.
Cell Death and Differentiation|January 26, 2021
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLLMarco Haselager, Rachel Thijssen, Christopher West, et al.
Haematologica|May 10, 2015
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitorsRachel Thijssen, Erik Slinger, Katinka Weller, et al.
Cell Death and Differentiation|June 20, 2020
Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cellsRachel Thijssen, Silvia Alvarez-Diaz, Clea Grace, et al.
Molecular Oncology|December 23, 2022
JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XLMarco V Haselager, Rachel Thijssen, Danique Bax, et al.
Oncogene|November 28, 2019
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphomaMichael A Dengler, Charis E Teh, Rachel Thijssen, et al.
Pageof 3